To enhance the effectiveness of GLP-1 RAs in managing pediatric obesity, we propose a comprehensive clinical medication use management process that includes review, screening, combination therapy, education, monitoring, and follow-up. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.